Patent ID: 7696403

Claim:
A method for identifying a therapeutic agent for an allergosis comprising, a. administering or contacting a Th2-mediated immune response initiating adjuvant in the presence or absence of a test substance to a sample, wherein said sample is i) a transgenic mouse model of Th2-mediated hyperimmune response whose genome comprises a homozygous disruption of the PIR-B gene causing a loss of functional PIR-B expression, wherein said homozygous disruption facilitates a hyperimmune response of B cells; ii) a tissue from said transgenic mouse model; iii) an organ from said transgenic mouse model; iv) or a cell derived from said trans genic mouse model; b. determining/evaluating an alteration of Th2-mediated immune response or PIR-A function from samples treated in the presence or absence of the test substance, and c. identifying the therapeutic agent for the allergosis, wherein a suitable therapeutic agent is the test substance that reduces the Th2-mediated immune response and/or enhances PIR-A function compared to when the test substance is absent.